GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (XSWX:OBSN) » Definitions » Operating Margin %

ObsEva (XSWX:OBSN) Operating Margin % : 38.53% (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is ObsEva Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. ObsEva's Operating Income for the three months ended in Dec. 2022 was CHF7.05 Mil. ObsEva's Revenue for the three months ended in Dec. 2022 was CHF18.29 Mil. Therefore, ObsEva's Operating Margin % for the quarter that ended in Dec. 2022 was 38.53%.

The historical rank and industry rank for ObsEva's Operating Margin % or its related term are showing as below:


XSWX:OBSN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.335
* Ranked among companies with meaningful Operating Margin % only.

ObsEva's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

ObsEva's Operating Income for the three months ended in Dec. 2022 was CHF7.05 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was CHF-15.07 Mil.


ObsEva Operating Margin % Historical Data

The historical data trend for ObsEva's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Operating Margin % Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only - - - -254.99 -79.83

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.40 - - - 38.53

Competitive Comparison of ObsEva's Operating Margin %

For the Biotechnology subindustry, ObsEva's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Operating Margin % distribution charts can be found below:

* The bar in red indicates where ObsEva's Operating Margin % falls into.



ObsEva Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ObsEva's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-14.605 / 18.294
=-79.83 %

ObsEva's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=7.048 / 18.294
=38.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ObsEva  (XSWX:OBSN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ObsEva Operating Margin % Related Terms

Thank you for viewing the detailed overview of ObsEva's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (XSWX:OBSN) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (XSWX:OBSN) Headlines

No Headlines